Acute myeloid leukemia classification: Difference between revisions

Jump to navigation Jump to search
Line 100: Line 100:
! Description
! Description
|-
|-
| '''Acute myeloid leukemia with characteristic genetic abnormalities'''
| '''Favorable risk'''
| Includes:
| Includes:


* AML with translocations between [[chromosome 8]] and 21 [t(8;21)] (ICD-O 9896/3); [[RUNX1]]/[[RUNX1T1]]
* AML with translocations between chromosome 8 and chromosome 21 [t(8;21)] (ICD-O 9896/3); [[RUNX1]]/[[RUNX1T1]]
* AML with inversions in [[chromosome 16]] [inv(16)] (ICD-O 9871/3); [[CBFB]]/[[MYH11]]
* AML with inversions in [[chromosome 16]] [inv(16)] (ICD-O 9871/3); [[CBFB]]/[[MYH11]]
* APL with translocations between [[chromosome 15]] and 17 [t(15;17)] (ICD-O 9866/3); [[Retinoic acid receptor alpha|RARA]];[[Promyelocytic leukemia protein|PML]]
* AML with mutant ''NPM1'' and wild-type ''FLT3''
* AML with biallelic CEBP''alpha'' mutation
|-
| '''Intermediate risk'''
| Includes:
* AML with mutant ''NPM1'' and mutant ''FLT3'' (''FLT3-ITD'')
* AML with wild-type ''NPM1'' and wild-type ''FLT3'' (no ''FLT3-ITD'')
* AML with translocations between chromosome 9 and chromosome 21 (''MLLT3-KMT2A'')
* AML with cytogenetic abnormalities not classified as favorable or adverse


Patients with acute myeloid leukemia in this category generally have a high rate of remission and a better prognosis compared to other types of acute myeloid leukemia.
|-
|-
| '''Acute myeloid leukemia with multilineage dysplasia'''
| '''Adverse risk'''
| This category includes patients who have had a prior [[myelodysplastic syndrome]] (MDS) or [[myeloproliferative disease]] (MPD) that transforms into acute myeloid leukemia.  This category of acute myeloid leukemia occurs most often in elderly patients and often has a worse prognosis.
| Includes:
|-
 
| '''Acute myeloid leukemia and MDS, therapy-related'''
* AML with translocations between chromosome 6 and chromosome 9
| This category includes patients who have had prior chemotherapy and/or radiation and subsequently develop acute myeloid leukemia or MDS.  These leukemias may be characterized by specific chromosomal abnormalities, and often carry a worse prognosis.
* AML with inversion of chromosome 3
* AML with translocations involving chromosome 11q23
* AML with translocations between chromosome 6 and chromosome 9
* AML with monosomy 5 or 7
* AML with complex karyotype (2 or more cytogenetic abnormalities)
* AML with mutant ''RUNX1'', ''ASXL1'', mutant ''TP53''
 
|-
|-
| '''Acute myeloid leukemia not otherwise categorized'''
| '''Acute myeloid leukemia not otherwise categorized'''

Revision as of 23:05, 23 October 2018

Acute myeloid leukemia Microchapters

Home

Patient Information

Overview

Historical Perspective

Classification

Pathophysiology

Causes

Differentiating Acute myeloid leukemia from other Diseases

Epidemiology and Demographics

Risk Factors

Screening

Natural History, Complications and Prognosis

Diagnosis

History and Symptoms

Physical Examination

Laboratory Findings

Electrocardigram

Chest X Ray

Echocardiograph and Ultrasound

CT

MRI

Other Imaging Findings

Other Diagnostic Studies

Treatment

Medical Therapy

Surgery

Primary Prevention

Secondary Prevention

Cost-Effectiveness of Therapy

Future or Investigational Therapies

Case Studies

Case #1

Acute myeloid leukemia classification On the Web

Most recent articles

Most cited articles

Review articles

CME Programs

Powerpoint slides

Images

American Roentgen Ray Society Images of Acute myeloid leukemia classification

All Images
X-rays
Echo & Ultrasound
CT Images
MRI

Ongoing Trials at Clinical Trials.gov

US National Guidelines Clearinghouse

NICE Guidance

FDA on Acute myeloid leukemia classification

CDC on Acute myeloid leukemia classification

Acute myeloid leukemia classification in the news

Blogs on Acute myeloid leukemia classification

Directions to Hospitals Treating Acute myeloid leukemia

Risk calculators and risk factors for Acute myeloid leukemia classification

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Raviteja Guddeti, M.B.B.S. [2] Carlos A Lopez, M.D. [3]

Overview

Acute myeloid leukemia may be classified according to the French-American-British (FAB) classification and World Health Organization (WHO).

Classification

There are 3 classifications systems for acute myeloid leukemia. These include the French-American-British (FAB) classification, the World Health Organization (WHO) classification, and the European LeukemiaNet (ELN) classification.

French-American-British classification

The French-American-British (FAB) classification system divided acute myeloid leukemia into 8 subtypes, M0 through to M7, based on the type of cell from which the leukemia developed and its degree of maturity. This is done by examining the appearance of the malignant cells under light microscopy and/or by using cytogenetics to characterize any underlying chromosomal abnormalities. The subtypes have varying prognoses and responses to therapy. Although the WHO classification (see below) may be more useful, the FAB system is still widely used as of mid-2006.

The eight FAB subtypes are:[1]

Type Name Cytogenetics
M0 Minimally differentiated AML
M1 Acute myeloblastic leukemia, without maturation
M2 Acute myeloblastic leukemia, with granulocytic maturation t(8;21)(q22;q22), t(6;9)
M3 Promyelocytic, or Acute promyelocytic leukemia (APL) t(15;17)
M4 Acute myelomonocytic leukemia inv(16)(p13q22), del(16q)
M4eo Myelomonocytic together with bone marrow eosinophilia inv(16), t(16;16)
M5 Acute monoblastic leukemia (M5a) or Acute monocytic leukemia (M5b) del (11q), t(9;11), t(11;19)
M6 Acute erythroid leukemias, including erythroleukemia (M6a) and very rare pure erythroid leukemia (M6b)
M7 Acute megakaryoblastic leukemia t(1;22)

World Health Organization classification

The World Health Organization (WHO) classification of acute myeloid leukemia attempts to be more clinically useful and to produce more meaningful prognostic information than the FAB criteria. Each of the WHO categories contains numerous descriptive sub-categories of interest to the hematopathologist and oncologist; however, most of the clinically significant information in the WHO schema is communicated via categorization into one of the five subtypes listed below.

The subtypes of acute myeloid leukemia are shown below:[2]

Name Description ICD-O
Acute myeloid leukemia with characteristic genetic abnormalities Includes:

Patients with acute myeloid leukemia in this category generally have a high rate of remission and a better prognosis compared to other types of acute myeloid leukemia.

Multiple
Acute myeloid leukemia with multilineage dysplasia This category includes patients who have had a prior myelodysplastic syndrome (MDS) or myeloproliferative disease (MPD) that transforms into acute myeloid leukemia. This category of acute myeloid leukemia occurs most often in elderly patients and often has a worse prognosis. Template:ICDO
Acute myeloid leukemia and MDS, therapy-related This category includes patients who have had prior chemotherapy and/or radiation and subsequently develop acute myeloid leukemia or MDS. These leukemias may be characterized by specific chromosomal abnormalities, and often carry a worse prognosis. Template:ICDO
Acute myeloid leukemia not otherwise categorized Includes subtypes of acute myeloid leukemia that do not fall into the above categories. Template:ICDO


European LeukemiaNet classification

Name Description
Favorable risk Includes:
  • AML with translocations between chromosome 8 and chromosome 21 [t(8;21)] (ICD-O 9896/3); RUNX1/RUNX1T1
  • AML with inversions in chromosome 16 [inv(16)] (ICD-O 9871/3); CBFB/MYH11
  • AML with mutant NPM1 and wild-type FLT3
  • AML with biallelic CEBPalpha mutation
Intermediate risk Includes:
  • AML with mutant NPM1 and mutant FLT3 (FLT3-ITD)
  • AML with wild-type NPM1 and wild-type FLT3 (no FLT3-ITD)
  • AML with translocations between chromosome 9 and chromosome 21 (MLLT3-KMT2A)
  • AML with cytogenetic abnormalities not classified as favorable or adverse
Adverse risk Includes:
  • AML with translocations between chromosome 6 and chromosome 9
  • AML with inversion of chromosome 3
  • AML with translocations involving chromosome 11q23
  • AML with translocations between chromosome 6 and chromosome 9
  • AML with monosomy 5 or 7
  • AML with complex karyotype (2 or more cytogenetic abnormalities)
  • AML with mutant RUNX1, ASXL1, mutant TP53
Acute myeloid leukemia not otherwise categorized Includes subtypes of acute myeloid leukemia that do not fall into the above categories.

References

  1. Bennett J, Catovsky D, Daniel M, Flandrin G, Galton D, Gralnick H, Sultan C (1976). "Proposals for the classification of the acute leukaemias. French-American-British (FAB) co-operative group". Br J Haematol. 33 (4): 451–8. PMID 188440.
  2. Vardiman J, Harris N, Brunning R (2002). "The World Health Organization (WHO) classification of the myeloid neoplasms". Blood. 100 (7): 2292–302. PMID 12239137. Full text.

Template:Hematology


Template:WikiDoc Sources